European Union: Safety Net For Safeners?

Last Updated: 7 August 2014
Article by Beatriz San Martín and Claudio Mereu

In the EU it is possible to obtain a supplementary protection certificate (SPC) for 'active substances' of a plant protection product (PPP) and 'active ingredients' of a medicinal product extending the protection afforded to such products beyond the patent term. Two distinct but related EC Regulations govern the grant of SPCs – Regulation No 1610/96 (the PPP SPC Regulation) and Regulation No. 469/2009 (the Medicinal Product SPC Regulation). It is generally accepted that equivalent provisions in the SPC Regulations should be interpreted in the same way but is this assumption correct?

The CJEU has considered the question of what is meant by 'product' and 'active ingredient' in the Medicinal Product SPC Regulation in a number of cases. The equivalent terms - 'product' and 'active substance' - in the PPP SPC Regulation have recently been considered by the CJEU in its decision of 19 June 2014 in the Bayer CropScience reference from the German Federal Patent Court in case C-11/13.

Bayer CropScience reference

By way of background, the applicant Bayer CropScience is the holder of a European patent, issued in Germany in 1994 covering isoxadifen, a safener - a substance intended to prevent the harmful action of a herbicide in plants. In March 2003, Bayer CropScience obtained a provisional marketing authorisation (MA) in Germany for the plant protection product Maister containing: foramsulfuron, iodosulfuron and isoxadifen. Shortly thereafter, in July 2003, Bayer CropScience applied to the German Patent and Trademark office for an SPC for the safener isoxadifen.

In 2007, the German Patent and Trademark office rejected the SPC application, which Bayer CropScience appealed. The German Federal Patent Court cited a number of factors for and against safeners being covered by the term 'active substance' (see table 1) before referring the case to the CJEU for a preliminary ruling. Consistent with the Opinion of 13 February 2014 of Advocate General Jääskinen, the CJEU has confirmed that it is possible for a safener to be covered by the terms 'product' and 'active substance' "where that substance has a toxic, phytotoxic or plant protection action of its own".

CJEU decision

In arriving at its decision, the CJEU noted that there was no express provision in the PPP SPC Regulation expressly preventing or allowing SPCs for safeners. The term 'active substances' in that Regulation relates to substances which have a toxic, phytotoxic or plant protection action of their own. Consequently, substances which do not act in this way cannot be the subject of an SPC. However, since the Regulation does not specify whether that action must be direct or indirect, there is no need to restrict the term 'active substances' to those substances whose action is direct.

Although the CJEU states in its decision that it is for the referring court to decide whether the safener at issue is an 'active substance', it adds that falling within the definition of 'active substances' is not enough and the four conditions in Article 3(1) of the PPP SPC Regulation still need to be satisfied. In particular, there must be a valid MA for the product as a plant protection product granted in accordance with Article 4 of Directive 91/414 or an equivalent provision of national law.

The CJEU has agreed with the AG that the grant of SPCs is regulated autonomously by the PPP SPC Regulation. Thus despite the link between the PPP SPC Regulation and Directive 91/414 governing the placing of plant protection products on the market (repealed and replaced by Regulation 1107/2009), the fact that Directive 91/414 does not treat safeners in the same way as active substances does not, on its own, prevent an SPC being granted for a safener. What is more important to the CJEU is whether the commercial exploitation of a patent for that safener has been delayed by the requirements in Directive 91/414.

Under Directive 91/414 active substances (as defined thereunder) must be listed in Annex I to the Directive and this list does not include safeners. Instead, safeners are regarded as 'co-formulants' and data concerning co-formulants must be included in the dossier in accordance with Annex III to the Directive. This requirement leads the CJEU to note that it is possible that the submission of a dossier for a plant protection product containing a safener has delayed the commercial exploitation of a patent for that safener. According to the CJEU, whether such delay has taken place will be important when the national court comes to decide whether a valid MA has been granted in accordance with Article 4 of Directive 91/414 for the condition in Article 3(1) of the PPP SPC Regulation to be satisfied.

Comment

A superficial reading of this latest CJEU decision could lead to the criticism that it is inconsistent with the decisions in MIT1 and GSK Biologicals2 relating to excipients and adjuvants for medicinal products and that a more liberal approach has been taken in relation to SPCs for plant protection products. The CJEU rejects such a proposition at paragraph 34 of the decision itself when it asserts that its interpretation "corresponds to that applied in respect of medicinal products, the Court already having had the opportunity to hold that a substance with no pharmaceutical effects of its own, such as an excipient or an adjuvant, does not constitute an active ingredient and, consequently, cannot give rise to the grant of a supplementary protection certificate". According to this logic, it should be possible for excipients and adjuvants of medicinal products to qualify for SPC protection if they are able to provide a therapeutic effect on their own.

The key to the CJEU decision is that the proposed active must have a toxic, phytotoxic or plant protection action of its own, such that, on the CJEU's reasoning, the same approach is being taken for both medicinal products and plant protection products. Despite the CJEU asserting that the PPP SPC Regulation is governed autonomously, their reasoning is hard to reconcile with the definitions of active substances and safeners under Regulation 1107/2009. Specifically, Article 2(3)(a) of that regulation defines safeners as "substances or preparations which are added to a plant protection product to eliminate or reduce phytotoxic effects of the plant protection product on certain plants". In other words, by definition safeners under this Regulation are not meant to have an independent active function of their own, but rather to operate in combination with other ingredients to reduce the activity of a plant protection product on certain plants.

It is interesting to note the emphasis placed by the CJEU on whether there has been regulatory delay in placing the safener in the market on the question of whether a valid MA has been granted. This purposive approach contrasts with MIT and GSK Biologicals (as well as other earlier cases) but is consistent with the approach taken in Neurim, Medeva and Georgetown I3. In this context, it is important to note that under the now applicable Regulation 1107/2009, repealing and replacing Directive 91/414, safeners shall be subject to the same requirements as active substances and included in a positive list of authorized safeners. Hence, in light of the fact that a regulatory approval with related delays in obtaining the approval is applicable for both safeners and active substances, the reasoning of the CJEU remains valid, thereby supporting the SPC for safeners.

As a corollary principle, a number of products currently regarded as 'fertilisers' or 'biostimulants', which have an indirect effect on the product, active substance and/or target organism and for which the Commission is currently assessing the need for new pre-marketing requirements, may need to be re-assessed for their potential to be covered by the definition of 'active substances' in the PPP SPC Regulation and therefore potentially qualify for SPC protection. This would be the case in particular if such products become subject to a similar regulatory regime as active substances/ingredients when seeking MAs where the applicant is considering applying for an SPC that includes one or more of those substances. This is because this will be a factor that national patent offices will need to consider when deciding whether to grant an SPC and whether the applicant has suffered regulatory delay in placing the product on the market.

The German Federal Patent Court has yet to apply this decision. It is open to debate whether the national court will, on the facts, come to the view that the safener isoxadifen has an action on its own and that all four conditions of Article 3(1) of the PPP SPC Regulation are satisfied to permit the grant of an SPC. We will also have to wait and see how national patent offices apply this latest decision – there is certainly scope yet again for inconsistent decisions in different Member States.

Table: The German Federal Patent Court's arguments for and against a safener being covered by the definition of 'active substance'

Safener = active substance

Safener ≠ active substance

  • The wording of Article 1 of the PPP SPC Regulation is compatible with 'active substance' covering safeners, bearing in mind a safener's effect on target organisms.
  • In Söll (C‑420/10, EU:C:2012:111), the CJEU held that 'biocidal products' also covers products that act only indirectly on the target harmful organisms, so long as they contain one or more active substances necessary to the process giving rise to the action sought.
  • Under Regulation 1107/2009, the conditions for approval of a safener are very largely the same as those required for the approval of an active substance.
  • Isoxadifen was examined for the approval of a provisional MA such that the granting of an SPC might be justified.
  • At best, safeners have an indirect effect by preventing the harmful effect of a herbicidal active substance.
  • In MIT (C-431/04, EU:C:2006:291), a substance that did not have any therapeutic effect on its own (in this case an excipient) was held not to be covered by the term 'active ingredient' in the Medicinal Product SPC Regulation.
  • Regulation 1107/2009 concerning the placing of plant protection products on the market and repealing Directives 79/117 and 91/414 distinguishes between active substances, safeners, synergists, co-formulants and adjuvants. Although the PPP SPC Regulation has not been amended accordingly, the term 'active substance' should be defined in the same way given the link between the two Regulations.
  • On the Commission's initiative, it is no longer necessary to declare and list safeners in Germany according to the same rules as those concerning active substances such that an SPC applicant might not be able to identify whether a third party has an MA for that safener. This indicates that safeners should not be treated in the same way as active substances.

Article first appeared in SPC Focus.

Footnotes

1. MIT C-431/04, EU:C:2006:291

2. GSK Biologicals C‑210/13, EU:C:2013:762

3. Cases C‑130/11, C‑322/10 and Case C‑422/10

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Beatriz San Martín
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.